Patient Derived Scaffolds (PDS) in Cancer Research and Drug Discovery

Recorded On: 09/22/2020

Breast cancer is a common malignancy with varying clinical behaviors and for the more aggressive subtypes, novel and more efficient therapy approaches are needed. Qualities of the tumor microenvironment as well as the presence of subtypes of cancer cells with various properties have separately been associated with malignant clinical features and better understanding of the interplay between these two key features could potentially reveal novel targetable key events linked to cancer progression. Since the cancer microenvironment influences tumor progression and metastasis it is further essential to include in the design of in vivo-like cancer models.

Current preclinical testing platforms for cancer drug development are mainly limited to 2D cell culture systems that poorly mimic physiological environments and traditional, low throughput animal models. Few models truly include the cancer microenvironments allowing the influence of the microenvironment to be monitored. We have therefore developed a patient derived scaffold (PDS) model that is based on cell-free patient scaffolds that can be repopulated with reporter cancer cells. The changes in the adapting cancer cells can then be monitored and specific influences on various key tumour biological properties can be enumerated. Within this project we have further defined the protein compositions of the cell-free scaffolds allowing us to construct 3D-printed surrogate scaffolds based on key proteins and agarose based prints, mimicking human like growth conditions facilitating high-throughput screenings of cancer drug candidates.

In this webinar, findings using PDS from breast and colon cancer will be described and links to clinical properties as well drug fingerprint based on in vivo-like growth conditions will be presented. The results using optimized 3D-printed surrogate scaffolds will also be delineated clearly illustrating the importance of including the cancer microenvironment in diagnostic and treatment predictive efforts as well as in the design of novel cancer drugs.

Göran Landberg, M.D., Ph.D.


University of Gothenburg

Göran Landberg has a highly competitive competence in molecular pathology based translational research and has established several national and international centers focusing on molecular pathology and breast cancer and has worked as professor and senior consultant in England and  Sweden. He is currently running a large research group focusing on cancer stem cells and the cancer microenvironment at the Sahlgrenska Cancer Center in Sweden linked to one of the largest hospitals in northern Europe. He has also started two companies focusing on novel diagnostic methods and therapies for breast cancer. Landberg has published more than 190 articles with an H-index of 63 and has supervised 25 Ph.D. students to graduation. The long-term goal within his research activities is to develop novel treatment principles for cancer patients better targeting true malignant features by understanding key tumour biological issues and properties including the tumour microenvironment.


Patient Derived Scaffolds (PDS) in Cancer Research and Drug Discovery
Open to view video.
Open to view video.